J 2006

Reduction of prefrontal gray matter volume in first-episode schizophrenia independent of risperidon treatment

KAŠPÁREK, Tomáš, Radovan PŘIKRYL, Daniel SCHWARZ, Hana KUČEROVÁ, Michal MIKL et. al.

Basic information

Original name

Reduction of prefrontal gray matter volume in first-episode schizophrenia independent of risperidon treatment

Name in Czech

Redukce prefrontální šedé kůry mozkové u první epizody schizofrenie a souvislost léčbou risperidonem.

Name (in English)

Reduction of prefrontal gray matter volume in first-episode schizophrenia independent of risperidon treatment

Authors

KAŠPÁREK, Tomáš (203 Czech Republic), Radovan PŘIKRYL (203 Czech Republic), Daniel SCHWARZ (203 Czech Republic), Hana KUČEROVÁ (203 Czech Republic), Michal MIKL (203 Czech Republic), Eva ČEŠKOVÁ (203 Czech Republic, guarantor) and Petr KRUPA (203 Czech Republic)

Edition

The International Journal of Neuropsychopharmacology, Cambridge, U.K. Cambridge University Press, 2006, 1461-1457

Other information

Language

Czech

Type of outcome

Článek v odborném periodiku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 5.184

RIV identification code

RIV/00216224:14110/06:00017087

Organization unit

Faculty of Medicine

UT WoS

000240771300244

Keywords in English

schizophrenia; gray matter; risperidone

Tags

gray matter, risperidone, schizophrenia
Změněno: 19/6/2009 14:41, prof. MUDr. Eva Češková, CSc.

Abstract

ORIG EN

V originále

In a group of first-episode schizophrenia patients gray matter reduction in prefrontal areas did not correlate with risperidone treatment parameters (cummulative dose, duration of treatment in days). The GM changes in these areas cannot be ascribed to the influence of the treatment with antipsychotics.

In English

In a group of first-episode schizophrenia patients gray matter reduction in prefrontal areas did not correlate with risperidone treatment parameters (cummulative dose, duration of treatment in days). The GM changes in these areas cannot be ascribed to the influence of the treatment with antipsychotics.

Links

MSM0021622404, plan (intention)
Name: Vnitřní organizace a neurobiologické mechanismy funkčních systémů CNS
Investor: Ministry of Education, Youth and Sports of the CR, The internal organisation and neurobiological mechanisms of functional CNS systems under normal and pathological conditions.
Displayed: 17/11/2024 10:07